Pretreatment Pokemon Level as a Predictor of Response to Cisplatin and Paclitaxel in Patients with Unresectable Non-Small Cell Lung Cancer

Publisher： Karger

E-ISSN： 2296-5262|38|10|496-502

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.38, Iss.10, 2015-0, pp. : 496-502

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Weekly Cetuximab and Gemcitabine plus Cisplatin as Salvage Therapy for Unresectable Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 32, Iss. 11, 2009-10 ,pp. : 685-686

Karger

Access to resources Recommend Favorite

Chemoradiotherapy in Locally Advanced, Unresectable Non-Small Cell Lung Cancer

By  

Reviews on Recent Clinical Trials, Vol. 4, Iss. 2, 2009-05 ,pp. : 110-121

Bentham Science Publishers

Access to resources Recommend Favorite

An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer

By Nuijten Mark J.C.   Aultman Rick   Carpeño Javier de Castro   Vergnenègre Alain   Chouaid Christos   Walzer Stefan   Siebert Uwe  

Current Medical Research and Opinion, Vol. 27, Iss. 11, 2011-11 ,pp. : 2193-2201

Informa Healthcare

Access to resources Recommend Favorite

Smoking History as a Predictor of Pemetrexed Monotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer

By  

Oncology, Vol. 91, Iss. 1, 2016-05 ,pp. : 41-47

Karger

Access to resources Recommend Favorite

Phase II Study of Weekly Paclitaxel in Patients with Non-Small Cell Lung Cancer Who Have Failed Previous Treatments

By  

Oncology, Vol. 66, Iss. 5, 2004-09 ,pp. : 347-352

Karger

Access to resources Recommend Favorite